A subset of gastrointestinal stromal tumors (GISTs) lack gain-of-function mutations in c-KIT
and PDGFR α. These so-called wild-type (WT) GISTs tend to be less responsive to imatinib …

Gastrointestinal stromal tumors (GISTs) have emerged from being poorly defined, treatment-
resistant tumors to a well-recognized, well-understood, and treatable tumor entity within only …

Wildtype (WT) gastrointestinal stromal tumors (GISTs), lacking mutations in KIT or PDGFRA,
represent 85% of GISTs in pediatric patients. Treatment options for pediatric WT GIST are …

Gastrointestinal stromal tumors (GISTs) may be defined as morphologically spindle cell,
epithelioid, or occasionally pleomorphic mesenchymal tumours of the gastrointestinal tract …

Aberrations of the Insulin‐like Growth Factor (IGF) system have been found in association
with a variety of cancer types. The potential role of IGF1R has been postulated in a small …

Purpose: Most gastrointestinal stromal tumors (GIST) have activating mutations of KIT,
PDGFRA, or uncommonly BRAF. Fifteen percent of adult and 85% of pediatric GISTs are …

Activating mutations in either KIT or PDGFRA are present in approximately 90% of
gastrointestinal stromal tumors (GIST). Although treatment with the KIT and PDGFR inhibitor …

Purpose: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal
tract. Nearly all tumors express KIT protein, and most have an activating mutation in either …

Introduction• Molecular pathogenesis of GIST• Imatinib and implications of mutation status
for the treatment of GIST• Imatinib resistance in GIST• Multi‐targeted tyrosine kinase …

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the
gastrointestinal tract. The name “GIST” was proposed in 1983, but the cell origin of GIST …